Business Context and Reporting Period
Company: Church & Dwight Co., Inc. (CHD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: The Company develops, manufactures, and markets consumer household, personal care, and specialty products. Key "power brands" include ARM & HAMMER, OXICLEAN, VITAFUSION, BATISTE, WATERPIK, THERABREATH, and HERO, which collectively represent approximately 70% of net sales and profits. Operations are divided into three segments: Consumer Domestic (77% of sales), Consumer International (18%), and Specialty Products Division (5%).
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Net Sales | $6,107.1 million | $5,867.9 million | +4.1% |
| Gross Profit | $2,790.1 million | $2,588.5 million | +7.8% |
| Gross Margin | 45.7% | 44.1% | +160 bps |
| Operating Income | $807.1 million | $1,057.4 million | -23.7% |
| Operating Margin | 13.3% | 18.0% | -470 bps |
| Net Income | $585.3 million | $755.6 million | -22.5% |
| Diluted EPS | $2.37 | $3.05 | -22.3% |
| Cash from Operations | $1,156.2 million | $1,030.6 million | +12.2% |
| Total Debt (Net) | $2,204.6 million | $2,202.2 million | Flat |
| Cash & Equivalents | $964.1 million | $344.5 million | +179.8% |
Material Changes vs. Prior Period
- Impairment Charges: Operating income and net income were significantly impacted by a non-cash impairment charge of $357.1 million related to the Vitamins, Minerals, and Supplements (VMS) business (VITAFUSION and L'IL CRITTERS brands). This charge reduced operating margin by 580 basis points and diluted EPS by $1.10. Excluding this charge, operating margin would have increased 110 basis points and diluted EPS would have been $3.47.
- Segment Performance:
- Consumer Domestic: Sales increased 3.5% driven by volumes and pricing, though offset by declines in VMS and WATERPIK shower heads.
- Consumer International: Sales increased 9.8% due to volume growth, pricing, and the Graphico acquisition, partially offset by foreign exchange headwinds.
- Specialty Products Division (SPD): Sales decreased 5.5% primarily due to the exit of the MEGALAC supplement business and the sale of the Passport food safety business.
- Acquisitions and Divestitures:
- Acquired Graphico, Inc. (Japan-based distributor) for $19.9 million net of cash.
- Sold the Passport food safety business for $6.6 million.
- Sold 50% interest in The ArmaKleen Company joint venture.
- Exited the MEGALAC supplement portion of the Animal Nutrition business.
- Tariff Ruling: Received a favorable tariff ruling resulting in $40.1 million in cash refunds, which reduced Cost of Goods Sold by $31.6 million and increased gross margin by approximately 50 basis points.
Guidance, Outlook, and Risks
- Dividend: The Board declared a 4% increase in the quarterly dividend to $0.295 per share, raising the annualized payout to approximately $287.0 million.
- Share Repurchases: No shares were repurchased under the public program in Q4 2024. Approximately $658.9 million remains available under the 2021 Share Repurchase Program.
- Capital Expenditures: Expected to be approximately $130.0 million in 2025, including investments in Therabreath and Sterimar manufacturing capacity and an ERP project.
- Key Risks:
- Competition: Intense competition in dietary supplements and private label growth, particularly impacting the VMS business.
- Consumer Behavior: Shifts to online shopping and value-branded products (e.g., WATERPIK consumers switching to value brands) impacting discretionary spending.
- Regulatory: Ongoing FDA scrutiny of OTC products, dietary supplements, and medical devices; potential impact of new global minimum tax (Pillar Two) rules.
- Supply Chain: Volatility in raw material costs (surfactants, resin) and energy prices.
Investor Verification Checklist
- VMS Business Outlook: Verify the sustainability of the VMS business strategy post-impairment and the specific initiatives to regain market share against private label competitors.
- WATERPIK Valuation: Monitor the fair value of the WATERPIK trade name ($644.7 million carrying value), which is susceptible to future impairment if consumer demand for discretionary products continues to decline.
- Customer Concentration: Confirm the stability of relationships with top customers, specifically Walmart, which accounted for 23% of consolidated net sales in 2024.
- Debt Maturity Profile: Review the maturity schedule of long-term debt (notably the 2027, 2031, 2032, 2047, and 2052 Senior Notes) and the company's ability to service debt given the fixed weighted average interest rate of 4.1%.
- Regulatory Compliance: Assess the impact of evolving FDA regulations on OTC monographs and dietary supplement labeling on product portfolios like ZICAM and HERO.